American Journal of Ophthalmology
Volume 146, Issue 5 , Pages 649-655.e6 , November 2008

Diabetic Macular Edema: What Is Focal and What Is Diffuse?

,Accepted 7 July 2008.

References 

  1. Krepler K, Wagner J, Sacu S, Wedrich A. The effect if intravitreal triamcinolone on diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol. 2005;243:478–481
  2. Negi AK, Vernon SA, Lim CS, Owen-Armstrong K. Intravitreal triamcinolone improves vision in eyes with chronic diabetic macular oedema refractory to laser photocoagulation. Eye. 2005;19:747–751
  3. Tunc M, Onder HI, Kaya M. Posterior sub-Tenon's capsule triamcinolone injection combined with focal laser photocoagulation for diabetic macular edema. Ophthalmology. 2005;112:1086–1091
  4. Ciardella AP, Klancnik J, Schiff W, Barile G, Langton K, Chang S. Intravitreal triamcinolone for the treatment of refractory diabetic macular edema with hard exudates: an optical coherence tomography study. Br J Ophthalmol. 2004;88:1131–1136
  5. Knudsen LL. Retrobulbar injection of methylprednisolone in diffuse diabetic macular edema. Retina. 2004;24:905–909
  6. Avci R, Kaderili B. Intravitreal triamcinolone injection for chronic diabetic macular oedema with severe hard exudates. Graefes Arch Clin Exp Ophthalmol. 2006;244:28–35
  7. Jonas JB, Kreissig I, Sofker A, Degenring RF. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol. 2003;121:57–61
  8. McDonald HR, Schatz H. Grid photocoagulation for diffuse macular edema. Retina. 1985;5:65–72
  9. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina. 2006;26:999–1005
  10. Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H, et al. Primary intravitreal bevacizumab (Avastin) for diabetic macular edema: results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology. 2007;114:743–750
  11. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. I (Maculopathy). Eye. 1998;12:69–76
  12. Kumar A, Sinha S, Azad R, Sharma YR, Vohra R. Comparative evaluation of vitrectomy and dye-enhanced ILM peel with grid laser in diffuse diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2007;245:360–368
  13. Abu El, Asrar AM, Morse PH. Laser photocoagulation control of diabetic macular oedema without fluorescein angiography. Br J Ophthalmol. 1991;75:97–99
  14. Aylward GW. Progressive changes in diabetics and their management. Eye. 2005;19:1115–1118
  15. Zein WM, Noureddin BN, Jurdi FA, Schakal A, Bashshur ZF. Panretinal photocoagulation and intravitreal triamcinolone acetonide for the management of proliferative diabetic retinopathy with macular edema. Retina. 2006;26:137–142
  16. Bresnick GH. Diabetic macular edema (A review). Ophthalmology. 1986;93:989–997
  17. Berman DH, Friedman EA. Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina. 1994;14:1–5
  18. Browning DJ. Diabetic macular edema: a critical review of the early treatment diabetic retinopathy study (ETDRS) series and subsequent studies. Compr Ophthalmol Update. 2000;1:69–83
  19. Greenstein VC, Chen H, Hood DC, Holopigian K, Seiple W, Carr RE. Retinal function in diabetic macular edema after focal laser photocoagulation. Invest Ophthalmol Vis Sci. 2000;41:3655–3664
  20. Greenstein VC, Holopigian K, Hood DC, Seiple W, Carr RE. The nature and extent of retinal dysfunction associated with diabetic macular edema. Invest Ophthalmol Vis Sci. 2000;41:3643–3654
  21. Gaucher D, Tadayoni R, Erginay A, Haouchine B, Gaudric A, Massin P. Optical coherence tomography assessment of the vitreoretinal relationship in diabetic macular edema. Am J Ophthalmol. 2005;139:807–813
  22. Kang SW, Park CY, Ham DI. The correlation between fluorescein angiographic and optical coherence tomographic features in clinically significant diabetic macular edema. Am J Ophthalmol. 2004;137:313–322
  23. Early Treatment Diabetic Retinopathy Study Research Group. Focal photocoagulation treatment of diabetic macular edema (Relationship of treatment effects to fluorescein angiographic and other retinal characteristics at baseline: ETDRS Report No. 19). Arch Ophthalmol. 1995;113:1144–1155
  24. Jonas JB, Martus P, Degenring RF, Kreissig I, Akkoyun I. Predictive factors for visual acuity after intravitreal triamcinolone treatment for diabetic macular edema. Arch Ophthalmol. 2005;123:1338–1343
  25. Cardillo JA, Melo LA, Costa RA, et al. Comparison of intravitreal versus posterior sub-tenon's capsule injection of triamcinolone acetonide for diffuse diabetic macular edema. Ophthalmology. 2005;112:1557–1563
  26. Blankenship GW. Diabetic macular edema and argon laser photocoagulation: a prospective randomized study. Ophthalmology. 1979;86:69–78
  27. Talwar D, Sharma N, Pai A, Azad RV, Kohli A, Virdi PS. Contrast sensitivity following focal laser photocoagulation in clinically significant macular oedema due to diabetic retinopathy. Clin and Experiment Ophthalmol. 2001;29:17–21
  28. Lovestam-Adrian M, Agardh E. Photocoagulation of diabetic macular oedema—complications and visual outcome. Acta Ophthalmol Scand. 2000;78:667–671
  29. Bonini-Filho MA, Jorge R, Barbosa JC, Calucci D, Cardillo JA, Costa RA. Intravitreal injection versus sub-Tenon's infusion of triamcinolone acetonide for refractory diabetic macular edema: a randomized clinical trial. Invest Ophthalmol Vis Sci. 2005;46:3845–3849
  30. Schmid KE, Neumaier-Ammerer B, Stolba U, Binder S. Effect of grid laser photocoagulation in diffuse diabetic macular edema in correlation to glycosylated haemoglobin (HbA1c). Graefes Arch Clin Exp Ophthalmol. 2006;244:1446–1452
  31. Otani T, Kishi S. Tomographic findings of foveal hard exudates in diabetic macular edema. Am J Ophthalmol. 2001;131:50–54
  32. Otani T, Kishi S. Tomographic assessment of vitreous surgery for diabetic macular edema. Am J Ophthalmol. 2000;129:487–494
  33. Thomas D, Laidlaw DA. OCT vitreoretinal interface patterns. Eye. 2003;17:541–542
  34. Shahidi M, Ogura Y, Blair NP, Zeimer R. Retinal thickness changes after focal laser treatment of diabetic macular oedema. Br J Ophthalmol. 1994;78:827–830
  35. Gibran SK, Cullinane A, Jungkim S, Cleary PE. Intravitreal triamcinolone for diffuse diabetic macular oedema. Eye. 2006;20:720–724
  36. Toda J, Fukushima H, Kato S. Injection of triamcinolone acetonide into the posterior sub-Tenon capsule for treatment of diabetic macular edema. Retina. 2007;27:764–769
  37. Neubauer AS, Kook D, Haritoglou C, et al. Bevacizumab and retinal ischemia. Ophthalmology. 2007;114:2096
  38. Ulbig MW, McHugh DA, Hamilton AM. Diode laser photocoagulation for diabetic macular oedema. Br J Ophthalmol. 1995;79:318–321
  39. Massin P, Duguid G, Erginay A, Haouchine B, Gaudric A. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol. 2003;135:169–177
  40. Watanabe M, Oshima Y, Emi K. Optical cross-sectional observation of resolved diabetic macular edema associated with vitreomacular separation. Am J Ophthalmol. 2000;129:264–267
  41. Jumper JM, Embabi SN, Toth CA, McCuen BW, Hatchell DL. Electron immunocytochemical analysis of posterior hyaloid associated with diabetic macular edema. Retina. 2000;20:63–68
  42. Arend O, Remky A, Harris A, Bertram B, Reim M, Wolf S. Macular microcirculation in cystoid maculopathy of diabetic patients. Br J Ophthalmol. 1995;79:628–632
  43. Chieh JJ, Roth DB, Liu M, et al. Intravitreal triamcinolone acetonide for diabetic macular edema. Retina. 2005;25:828–834
  44. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema (Early Treatment Diabetic Retinopathy Study Report No. 1). Arch Ophthalmol. 1985;103:1796–1806
  45. Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003;110:1677–1682
  46. Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol. 2005;140:200–206
  47. Patz A. Cystoid maculopathy in diabetics. Arch Ophthalmol. 1976;94:761–768
  48. Jensen DB, Knudsen LL. Stereoscopic fluorescein angiography in diabetic maculopathy. Retina. 2006;26:153–158
  49. Jeppesen P, Bek T. Impaired retinal autoregulation in small retinal arterioles before and after focal laser treatment for diabetic maculopathy. Br J Ophthalmol. 2006;90:198–201
  50. Laursen ML, Moeller F, Sander B, Sjoelie AK. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol. 2004;88:1173–1179
  51. Kinyoun J, Barton F, Fisher M, Hubbard L, Aiello L, Ferris FL. Detection of diabetic macular edema (Ophthalmoscopy versus photography—Early Treatment Diabetic Retinopathy Study Report No. 5. The ETDRS Research Group). Ophthalmology. 1989;96:746–750discussion 750–751
  52. Sander B, Larsen M, Engler C, et al. Diabetic macular oedema: a comparison of vitreous fluorometry, angiography, and retinopathy. Br J Ophthalmol. 2002;86:316–320
  53. Early Treatment Diabetic Retinopathy Study Research Group. Classification of diabetic retinopathy from fluorescein angiograms (ETDRS Report No. 11). Ophthalmology. 1991;98:807–822
  54. Wallow IH, Bindley CD. Focal photocoagulation of diabetic macular edema (A clinicopathologic case report). Retina. 1988;8:261–269
  55. Yanyali A, Nohutcu AF, Horozoglu F, Celik E. Modified grid laser photocoagulation versus pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Am J Ophthalmol. 2005;139:795–801
  56. Gandorfer A, Messmer EM, Ulbig MW, Kampik A. Resolution of diabetic macular edema after surgical removal of the posterior hyaloid and the inner limiting membrane. Retina. 2000;20:126–133
  57. Lee CM, Olk RJ. Modified grid laser photocoagulation for diffuse diabetic macular edema (Long-term visual results). Ophthalmology. 1991;98:1594–1602
  58. Akduman L, Olk RJ. Subthreshold (invisible) modified grid diode laser photocoagulation in diffuse diabetic macular edema (DDME). Ophthalmic Surg Lasers. 1999;30:706–714
  59. Lee CM, Olk RJ, Akduman L. Combined modified grid and panretinal photocoagulation for diffuse diabetic macular edema and proliferative diabetic retinopathy. Ophthalmic Surg Lasers. 2000;31:292–300
  60. Akduman L, Olk RJ. Laser photocoagulation of diabetic macular edema. Ophthalmic Surg Lasers. 1997;28:387–408
  61. Yanyali A, Horozoglu F, Celik E, Nohutcu AF. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina. 2007;27:557–566
  62. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology. 2002;109:920–927
  63. Diabetic Retinopathy Clinical Research NetworkScott IU, Edwards AR, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology. 2007;114:1860–1867
  64. Kylstra JA, Brown JC, Jaffe GJ, et al. The importance of fluorescein angiography in planning laser treatment of diabetic macular edema. Ophthalmology. 1999;106:2068–2073
  65. Browning DJ, Fraser CM. Regional patterns of sight-threatening diabetic macular edema. Am J Ophthalmol. 2005;140:117–124
  66. Sadda SR, Tan O, Walsh AC, Schuman JS, Varma R, Huang D. Automated detection of clinically significant macular edema by grid scanning optical coherence tomography. Ophthalmology. 2006;113:1187;el–e12
  67. Kim BY, Smith SD, Kaiser PK. Optical coherence tomographic patterns of diabetic macular edema. Am J Ophthalmol. 2006;142:405–412
  68. Brasil OF, Smith SD, Galor A, Lowder CY, Sears JE, Kaiser PK. Predictive factors of short-term visual outcome after intravitreal triamcinolone acetonide injection for diabetic macular oedema: an optical coherence tomography study. Br J Ophthalmol. 2007;91:761–765
  69. Browning DJ, McOwen MD, Bowen RM, O'Marah TL. Comparison of the clinical diagnosis of diabetic macular edema with diagnosis by optical coherence tomography. Ophthalmology. 2004;111:712–715
  70. Audren F, LeCleire-Collet A, Erginay A, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema: phase 2 trial comparing 4 mg vs 2 mg. Am J Ophthalmol. 2006;142:794–799
  71. Shulman S, Ferencz JR, Gilady G, Ton Y, Assia E. Prognostic factors for visual acuity improvement after intravitreal triamcinolone injection. Eye. 2007;21:1067–1070
  72. Carpineto P, Ciancaglini M, Di Antonio L, Gavalas C, Mastropasqua L. Fundus microperimetry patterns of fixation in type 2 diabetic patients with diffuse macular edema. Retina. 2007;27:21–29
  73. Shimura M, Yasuda K, Nakazawa T, Ota S, Tamai M. Effective treatment of diffuse diabetic macular edema by temporal grid pattern photocoagulation. Ophthalmic Surg Lasers Imaging. 2004;35:270–280
  74. Kang SW, Sa HS, Cho HY, Kim JI. Macular grid photocoagulation after intravitreal triamcinolone acetonide for diffuse diabetic macular edema. Arch Ophthalmol. 2006;124:653–658
  75. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology. 2004;111:218–224
  76. Audren F, Tod M, Massin P, et al. Pharmacokinetic-pharmacodynamic modeling of the effect of triamcinolone ecetonide on central macular thickness in patients with diabetic macular edema. Invest Ophthalmol Vis Sci. 2004;45:3435–3441
  77. Lobo CL, Bernardes RC, de Abreu JR, Cunha-Vaz JG. One-year follow-up of blood-retinal barrier and retinal thickness alterations in patients with type 2 diabetes mellitus and mild nonproliferative retinopathy. Arch Ophthalmol. 2001;119:1469–1474
  78. Lobo CL, Bernardes RC, Cunha-Vaz JG. Alternations of the blood-retinal barrier and retinal thickness in preclinical retinopathy in subjects with type 2 diabetes. Arch Ophthalmol. 2000;118:1364–1369
  79. Bailey CC, Sparrow JM, Grey RH, Cheng H. The National Diabetic Retinopathy Laser Treatment Audit. III (Clinical outcomes). Eye. 1999;13:151–159
  80. Khairallah M, Zeghidi H, Ladjimi A, et al. Primary intravitreal triamcinolone ecetonide for diabetic massive macular hard exudates. Retina. 2005;25:835–839
  81. Spandau UH, Derse M, Schmitz-Valckenberg P, Papoulis C, Jonas JB. Dosage dependency of intraviteal triamcinolone ecetonide as treatment for diabetic macular oedema. Br J Ophthalmol. 2005;89:999–1003
  82. Diabetic Retinopathy Clinical Research Network. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology. 2007;114:525–536
  83. Bresnick GH. Diabetic maculopathy (A critical review highlighting diffuse macular edema). Ophthalmology. 1983;90:1301–1317
  84. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol. 2005;89:74–80
  85. Shimura M, Nakazawa T, Yasuda K, Shiono T, Nishida K. Pretreatment of posterior sub-Tenon injection of triamcinolone acetonide has beneficial effects for grid pattern photocoagulation against diffuse diabetic macular oedema. Br J Ophthalmol. 2007;91:449–454
  86. Funatsu H, Yamashita H, Ikeda T, Mimura T, Shimizu E, Hori S. Relation of diabetic macular edema to cytokines and posterior vitreous detachment. Am J Ophthalmol. 2003;135:321–327

 Supplemental Material available at AJO.com.

PII: S0002-9394(08)00533-3

doi: 10.1016/j.ajo.2008.07.013

American Journal of Ophthalmology
Volume 146, Issue 5 , Pages 649-655.e6 , November 2008

Article Tools